This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
Home
Products
Trurapi®▼ (insulin aspart 100 units/mL)
Trurapi Hero Pen

Trurapi®

insulin aspart 100 units/mL

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

The first rapid acting insulin biosimilar of NovoRapid® approved in the UK and EU.1

Profile

30% lower NHS list price vs. NovoRapid® pre-filled pens and cartridges and 15% lower NHS list price vs. NovoRapid® vials.2

1:1 initial unit dosing - available in the SoloStar pen, cartridges and vials1*

*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1

Similar PK/PD profile (T1DM),efficacy, safety and tolerability (T1DM and T2DM).3-4

1/3

30% lower NHS list price vs. NovoRapid® pre-filled pens and cartridges and 15% lower NHS list price vs. NovoRapid® vials.2

1:1 initial unit dosing - available in the SoloStar pen, cartridges and vials1*

*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1

Similar PK/PD profile (T1DM),efficacy, safety and tolerability (T1DM and T2DM).3-4

Diabetes Stories

Watch peer-to-peer videos of payors and healthcare professionals sharing best practices of adopting a rapid acting insulin biosimilar. Some of these videos are related to HCPs sharing their experiences with a different rapid acting insulin biosimilar.

Start and Switch

Watch and download resources to support your rapid acting insulin adoption.

Sohail Akhtar - 19.02.24 - 16:56

Print and distribute this card for your patient to enable an easy access to support materials.

Trurapi Leaflet

This leaflet gives you an overview of the clinical evidence, price comparison of Trurapi® versus NovoRapid® and information on 1:1 dosing and the different presentations available.

Formulary FAQ

This FAQ document provides factual and technical information about Trurapi® to support you with relevant documentation for local formulary applications.

Trurapi Poster

Pharmacists and other Healthcare Professionals can print this poster and put it in drug fridges to provide information about Trurapi.

Slide Deck

This slide deck can be used to support Health Care Professional training on Trurapi®. It gives an overview of the clinical evidence, information on 1:1 dosing, the different presentations available and price comparison of Trurapi® versus NovoRapid®.

Retailer Query

This document supports medicines management teams and clinical customers to deal with retailer queries on how to purchase Trurapi®️.

What is a Biosimilar Medicine?

Length: 07:04

Get the answer in this video by Nurse Consultant in Diabetes, Grace Vanterpool or read the video summary.

Diabetes Stories

Length: 04:02

You can watch briefly how a payor, an endocrinologist and a diabetes specialist nurse implemented a rapid acting biosimilar insulin in their local region and how they collaborated with clinical teams and patients to make a positive start and switch.

Get in touch with the Diabetes Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023

MAT-XU-2205461 (v9.0)  Date of Preparation: February 2024